Syng Pharmaceuticals Inc.

$0.00 CAD

Department: National Research Council Canada
Program: Industrial Research Assistance Program – Contributions to Firms
Recipient country: Canada
Fiscal year: 2017-2018
Agreement period: October 2, 2017 – June 30, 2018
Reference: nrc-cnrc:172-2018-2019-Q1-893052

Published purpose

SYNG Pharma is developing first, in vitro test for endometriosis. This project will validate analytical methods for antigen antibody detection using different matrices, development of lateral flow device and generate new IP for detection of a new biomarker for endometriosis.

Community tags

Tags are applied by readers, not by this site. One tag per person per record.

Good value Local impact Needs context Questionable Success story Wasteful

View official source record Imported July 30, 2026 from open.canada.ca Grants & Contributions